Abstract:Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has progressed to a pandemic associated with substantial morbidity and mortality. The WHO and the United States Center for Disease Control and Prevention (CDC) have issued interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19), but there is limited data on the virologic and clinical characteristics for prognosis of severe COVID-19. Methods A total of 50 patients with severe COVID-19 were divided into good and poor recovery groups. The dynamic viral shedding and serological characteristics of SARS-CoV-2 were explored. The risk factors associated with poor recovery and lung lesion resolutions were identified. In addition, the potential relationships among the viral shedding, the pro-inflammatory response, and lung lesion evolutions were characterized. Results A total of 58% of the patients had poor recovery and were more likely to have a prolonged interval of viral shedding. The longest viral shedding was 57 days after symptom onset. Older age, hyperlipemia, hypoproteinemia, corticosteroid therapy, consolidation on chest computed-tomography (CT), and prolonged SARS-CoV-2 IgM positive were all associated with poor recovery. Additionally, the odds of impaired lung lesion resolutions were higher in patients with hypoproteinemia, hyperlipemia, and elevated levels of IL-4 and ferritin. Finally, viral shedding and proinflammatory responses were closely correlated with lung lesion evolutions on chest CT. Conclusions Patients with severe COVID-19 have prolonged SARS-CoV-2 infection and delayed intermittent viral shedding. Older age, hyperlipemia, hypoproteinemia, corticosteroid usage, and prolonged SARS-CoV-2 IgM positive might be utilized as predicative factors for the patients with poor recovery. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by grants from the 13th Five-Year National Science and Technology Major Projects (grant number: 2016X10002003). ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Availability of all data requests to Dr. Yi Ouyang at the Department of Infectious Diseases, Xiangya Hospital, Central South University, Xiangya Rd 87#. Changsha 410008, P.R.China, or at doctor-ouyang@csu.edu.cn

Viral and Host Factors Related to the Clinical Outcome of COVID-19

Viral and host factors related to the clinic outcome of the SARS CoV 2 infection

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Host susceptibility to severe COVID-19: a retrospective analysis of 487 case outside Wuhan

Association of Clinical and Immunological Characteristics With Disease Severity and Outcomes in 211 Patients With COVID-19 in Wuhan, China

Clinical and Pathological Investigation of Patients with Severe COVID-19

Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019

Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China

Virologic and clinical characteristics for prognosis of severe COVID 19: a retrospective observational study in Wuhan, China

Risk Factors for Disease Severity in COVID-19 Patients: A Single-Center Retrospective Study

Clinical Characteristics and Co-Infections of 354 Hospitalized Patients with COVID-19 in Wuhan, China: a Retrospective Cohort Study

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Clinical Characteristics and Short-Term Outcomes of Severe Patients With COVID-19 in Wuhan, China

Epidemiological, Clinical, and Virological Characteristics of 465 Hospitalized Cases of Coronavirus Disease 2019 (COVID-19) from Zhejiang Province in China

Clinical Course and Outcome of 107 Patients Infected with the Novel Coronavirus, SARS-CoV-2, Discharged from Two Hospitals in Wuhan, China.

Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19

A Chinese Host Genetic Study Discovered Type I Interferons and Causality of Cholesterol Levels and WBC Counts on COVID-19 Severity

Clinical Features and Short-Term Outcomes of 221 Patients with COVID-19 in Wuhan, China.

Elevated Plasma Levels of Selective Cytokines in COVID-19 Patients Reflect Viral Load and Lung Injury.